Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | GFER | P55789 | 3/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23551424 | 0.86 | ALDH1A1 (0.47) | LGMNMAPTKDM4EGAALMNA | |
| SCHEMBL13114895 | 0.86 | GFER (0.48) | MAPTGFERCASP6KDM4EGAA | |
| SCHEMBL22657728 | 0.86 | ATM (0.51) | MAPTKDM4EGAALMNAPARP14 | |
| SCHEMBL180951 | 0.85 | GPR119 (0.48) | LGMNMAPTKDM4EGAALMNA | |
| SCHEMBL14511132 | 0.85 | PIK3CA (0.46) | LGMNMAPTPARP14 | |
| SCHEMBL14511126 | 0.84 | HRH3 (0.46) | LGMNMAPTKDM4EGAALMNA | |
| SCHEMBL6794440 | 0.84 | F10 (0.47) | MAPTKDM4EGAALMNACYP3A4 | |
| SCHEMBL16969213 | 0.84 | FFAR4 (0.41) | LGMNMAPTGFERCASP6KDM4E | |
| SCHEMBL12631704 | 0.83 | NOTUM (0.49) | MAPTKDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL7753345 | 0.83 | USP14 (0.52) | MAPTKDM4EGAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| CN-116529252-A | Prodrugs for sustained release of therapeutic agents and uses thereof | 重庆两江药物研发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| US-8772494-B2 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-07-08 | — | — | US | disclosed |
| US-8258304-B2 | N-aryl piperidine substituted biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-1694644-B1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-07 | — | — | EP | disclosed |
| US-8115011-B2 | (S)-3-{5-[(1-Pyridin-2-yl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-ylamino}-pyrrolidine-1-carboxylic acid ethyl ester; obesity, type II diabetes mellitus and metabolic syndrome | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-8058299-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-1536796-B1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-1694644-A2 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-30 | — | — | EP | disclosed |
| US-20060040989-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| CN-1665789-A | Diaminopyrimidinecarboxa mide derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| WO-2005058824-A2 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTE IN B | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1536796-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-08 | — | — | EP | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004017969-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | GRPR, SLC2A8, HPGDS | LGMN 719/4885MAPT 2768/4885GFER 2136/4885 |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | LGMN 4677/4885MAPT 4703/4885GFER 3359/4885 |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | APOB, PNLIP, LIPC | LGMN 1502/4885MAPT 4151/4885GFER 2606/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | LGMN 4806/4885MAPT 4551/4885GFER 3764/4885 |
| US-20060040989-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | APOB, PNLIP, LPL | LGMN 1361/4885MAPT 4272/4885GFER 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.